Stem Cells Spin Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Stem Cells Spin has been growing earnings at an average annual rate of 43.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 7.6% per year.
Key information
43.6%
Earnings growth rate
43.6%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | -7.6% |
| Return on equity | -2.1% |
| Net Margin | -36.7% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Stem Cells Spin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 1 | 0 | 0 | 0 |
| 30 Sep 21 | 1 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 1 | -1 | 0 | 0 |
| 31 Dec 19 | 1 | -1 | 0 | 0 |
| 30 Sep 19 | 1 | -1 | 0 | 0 |
| 30 Jun 19 | 0 | -1 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
| 31 Dec 18 | 1 | -1 | 0 | 0 |
| 30 Sep 18 | 1 | 0 | 0 | 0 |
| 30 Jun 18 | 1 | 0 | 0 | 0 |
| 31 Mar 18 | 1 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 1 | 0 | 0 | 0 |
| 30 Jun 17 | 1 | 0 | 0 | 0 |
| 31 Mar 17 | 1 | 0 | 0 | 0 |
| 31 Dec 16 | 1 | 0 | 0 | 0 |
| 30 Sep 16 | 1 | 1 | 1 | 0 |
| 30 Jun 16 | 2 | 1 | 1 | 0 |
| 31 Mar 16 | 2 | 1 | 1 | 0 |
| 31 Dec 15 | 2 | 1 | 1 | 0 |
| 30 Sep 15 | 1 | 0 | 1 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 1 | 0 | 0 | 0 |
| 30 Sep 14 | 1 | 0 | 0 | 0 |
| 30 Jun 14 | 1 | 0 | 0 | 0 |
| 31 Mar 14 | 1 | 0 | 1 | 0 |
| 31 Dec 13 | 1 | 0 | 1 | 0 |
| 30 Sep 13 | 1 | 0 | 0 | 0 |
| 30 Jun 13 | 1 | 0 | 1 | 0 |
Quality Earnings: SCS is currently unprofitable.
Growing Profit Margin: SCS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCS is unprofitable, but has reduced losses over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare SCS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: SCS has a negative Return on Equity (-2.07%), as it is currently unprofitable.